天境生物科技（上海）有限公司 IMab
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange 2021-07-27 20:35
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms 2021-07-09 20:00
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio 2021-07-01 20:00
I-Mab Honored with Top Rankings by Institutional Investor 2021-06-30 20:00
I-Mab Announces Upcoming Participation at July Conference 2021-06-29 20:00
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus 2021-06-25 20:00
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board 2021-06-21 20:00
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 2021-05-20 06:00
I-Mab Added to MSCI China Index 2021-05-13 20:00
I-Mab Announces Upcoming Participation at May Conferences 2021-04-29 20:00
I-Mab Filed 2020 Annual Report on Form 20-F 2021-04-28 20:00
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis 2021-04-26 19:00
I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021 2021-03-03 21:00
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency 2021-02-25 21:00
I-Mab Announces Upcoming Participation at March Conferences 2021-02-24 21:00
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors 2021-02-10 21:00
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced 2021-02-09 21:00
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab 2021-02-06 06:27
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S. 2021-02-05 21:00
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China 2021-02-04 21:00
1 3 4 5 6 7 8